Sage Therapeutics is discontinuing the development of dalzanemdor after the investigational therapy failed to improve cognitive abilities relative to a placebo among people with Huntington’s disease enrolled in a Phase 2 clinical trial. Statistically significant gains in cognition with treatment was the main goal of the…

Significant impairments in cognitive function are evident in people with Huntington’s disease relative to healthy adults, as assessed with a disease-specific battery of cognitive tests, top-line data from a Phase 2 clinical trial show, meeting its main goal. The two-part trial, called SURVEYOR (NCT05358821), also evaluated the safety…

My wife, Jill, and I recently celebrated 15 years of marriage. When we said “I do” all those years ago, I couldn’t have guessed what would eventually happen to her: She is being robbed of her words. Or, as she puts it, words are “escaping” her. Jill will be…

Sage Therapeutics is recruiting participants for a clinical trial to test the effects of its experimental therapy SAGE-718 on cognitive symptoms in people with Huntington’s disease. The Phase 2 study, called DIMENSION (NCT05107128), is seeking participants in select regions of the U.S. with additional sites in the…

This past summer, I had to take my car to a mechanic. It had logged more than 122,000 miles and needed some major work done to it. My wife, Jill, went with me but she drove her car so I could leave mine at the mechanic’s shop, which…

AMT-130, uniQure’s experimental gene therapy candidate for Huntington’s disease, halts shrinkage of certain brain regions and helps preserve cognitive function in a mouse model of the disease, preclinical data show. Additionally, a single dose of AMT-130 reduced the levels of mutated huntingtin (HTT) — the protein that…

People with Huntington’s disease who develop psychosis tend to have worse cognitive and behavioral disturbances, reduced ability to function, and fewer involuntary movements than patients who do not experience these psychiatric symptoms, a new study reports. The study, titled “Psychosis and longitudinal outcomes in Huntington disease: the…

Being less affected by loss is predictive of apathy in people with Huntington’s disease (HD), a new study has found. The study, “Insensitivity to Loss Predicts Apathy in Huntington’s Disease,” was published in the journal Movement Disorders. Apathy — the feeling of indifference, where a person just doesn’t care —…

Differences in the activity of a protein called Cdk5 in the brain could be a cause of — and perhaps even a target for the treatment of — depression related to Huntington’s disease, research in mice suggests. The study, “Cyclin-Dependent Kinase 5 Dysfunction Contributes to Depressive-like Behaviors…

EIP Pharma is launching a proof-of-concept Phase 2 clinical trial to assess the ability of therapeutic candidate neflamapimod to treat cognitive dysfunction in patients with early-stage Huntington’s disease. The trial (NCT03980938), which is currently recruiting, is taking place at the John Van Geest Centre for…